Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $69.26 USD
Change Today -3.74 / -5.12%
Volume 538.6K
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

sage therapeutics inc (SAGE) Snapshot

Open
$73.11
Previous Close
$73.00
Day High
$73.11
Day Low
$67.35
52 Week High
06/9/15 - $89.04
52 Week Low
07/29/14 - $24.25
Market Cap
2.0B
Average Volume 10 Days
598.4K
EPS TTM
$-6.10
Shares Outstanding
28.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGE THERAPEUTICS INC (SAGE)

sage therapeutics inc (SAGE) Related Businessweek News

No Related Businessweek News Found

sage therapeutics inc (SAGE) Details

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat life-threatening and rare central nervous system disorders. The company’s lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its pipeline also includes second-generation molecules, such as SAGE-217, an oral therapy for orphan genetic epilepsies; and SAGE-689, an adjunctive intravenous second-line therapy for the treatment of refractory status epilepticus. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

29 Employees
Last Reported Date: 05/15/15
Founded in 2010

sage therapeutics inc (SAGE) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $550.0K
Chief Medical Officer
Total Annual Compensation: $390.0K
Chief Scientific Officer
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

sage therapeutics inc (SAGE) Key Developments

SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of Sage-547 in Postpartum Depression

SAGE Therapeutics announced top-line data from an exploratory clinical trial that indicate a statistically significant improvement from baseline in depression in four women with postpartum depression (PPD) within 24 hours after administration of intravenous SAGE-547 (paired t-test p=0.001). During the SAGE-547 treatment period, all four patients rapidly achieved remission, as measured by the Hamilton Rating Scale for Depression (HAM-D). The patients had a mean HAM-D score of 26.5 at baseline and improved to a mean HAM-D score of 1.8 at the end of the 60-hour treatment period. All four patients also demonstrated consistent improvement as measured by the Clinical Global Impression-Improvement (CGI-I) scale. SAGE-547 was well-tolerated in all patients treated with no serious adverse events observed on therapy or during the 30-day follow-up period. PPD is estimated to affect up to 20% of women following childbirth. The HAM-D scale is used by clinicians to rate the severity of 17 symptoms observed in depression, such as low mood, insomnia, agitation, anxiety and weight loss. A HAM-D rating of greater than 24.0 is considered severe and a score below 7.0 is considered symptom-free. The exploratory open-label trial recruited women with PPD for treatment with a proprietary dosing schedule of SAGE-547 as an adjunctive therapy, a therapy combined with current therapeutic approaches. The trial was designed to provide data regarding safety, tolerability, pharmacokinetics and the acute effect of SAGE-547 on depressive symptoms as measured by the HAM-D and CGI-I. All of the patients enrolled had a Major Depressive Episode, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and were treated as inpatients. All four patients had an inadequate response to prior antidepressant therapy. The initial trial planned to enroll up to 15 patients or until 10 patients were deemed to be evaluable, whichever occurred first, aged 18 to 45 years, but after the consistent responses observed, the initial findings justified accelerating the program into a placebo-controlled trial. SAGE-547 was well-tolerated with no serious adverse events reported during the treatment and follow-up periods and no discontinuations due to adverse events. A total of 14 adverse events were reported in four patients. The only adverse event reported in more than one patient was sedation, observed in two patients.

Sage Therapeutics, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 10:00 AM

Sage Therapeutics, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 10:00 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Jeffrey M. Jonas, Chief Executive Officer, President, Director and Member of Science & Technology Committee.

Sage Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reports Successful Completion of Phase 1/2 Clinical Trial of SAGE-547 in SRSE

Sage Therapeutics, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. Net loss attributable to common stockholders was $16.9 million for the first quarter of 2015 compared to net loss of $6.1 million for the first quarter of 2014. Loss from operations was $16,897,000 against $5,790,000 a year ago. Net loss per share attributable to common stockholders-basic and diluted was $0.66 against $3.70 a year ago. The company announced the successful completion of Phase 1/2 clinical trial of SAGE-547 in SRSE, demonstrating SAGE-547's strong and robust activity and favorable safety profile. It believes this novel product candidate offers the potential to be developed as the first approved therapy for SRSE, providing hope to patients and their families affected by this rare and life-threatening seizure disorder.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAGE:US $69.26 USD -3.74

SAGE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SAGE.
View Industry Companies
 

Industry Analysis

SAGE

Industry Average

Valuation SAGE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 17.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGE THERAPEUTICS INC, please visit www.sagerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.